Vicapsys Life Sc Stock Price, News & Analysis
Company Description
Vicapsys Life Sc (OTC Link: VICP) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $57.3M.
VICP stock has declined 2.7% over the past year. Shares last traded at $1.46.
On a trailing twelve-month basis, Vicapsys Life Sc and diluted earnings per share of $-0.03.
This page provides a comprehensive overview of VICP stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Vicapsys Life Sc (VICP) stock last traded at $1.46. Over the past 12 months, the stock has lost 2.7%. At a market capitalization of $57.3M, VICP is classified as a micro-cap stock with approximately 32.4M shares outstanding.
VICP Rankings
Latest News
Vicapsys Life Sc has 2 recent news articles. Key topics include management. View all VICP news →
SEC Filings
Financial Highlights
Diluted earnings per share stood at $-0.03. With a current ratio of 0.02, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Short interest in Vicapsys Life Sc (VICP) currently stands at 43 shares, representing 0.0% of the float. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Vicapsys Life Sc (VICP) currently stands at 1.0 days, down 99.9% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has decreased 99.9% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 1.0 to 1000.0 days.
VICP Company Profile & Sector Positioning
Vicapsys Life Sc (VICP) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing VICP often look at related companies in the same sector, including Medicenna Therapeutics Corp (MDNAF), Hemogenyx Pharma (HOPHF), Nurexone Biologic Inc (NRXBF), Helix Biopharma (HBPCF), and Arch Biopartners (ACHFF). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate VICP's relative position within its industry.